Dianthus Therapeutics, Inc.

Frequently Asked Questions About DNTH

How is DNTH valued?

Dianthus Therapeutics, Inc. (DNTH)'s valuation is shown across multiple multiples on this page (P/E, P/B, P/S, EV/EBITDA, P/FCF) with both current and historical context. When trailing earnings are negative, forward-looking multiples and revenue / cash-flow ratios become more relevant.

Is DNTH undervalued or overvalued?

Dianthus Therapeutics, Inc.'s current valuation multiples are compared against the stock's own historical range and against sector peers on this page. A multiple in the lowest percentile of its 10-year history is typically considered undervalued, with caveats. The analyst price target card adds another data point.

What is the analyst price target for DNTH?

The Wall Street price-target card on this page shows the consensus 12-month price target for Dianthus Therapeutics, Inc. (DNTH), the high and low range, and the implied upside or downside vs the current share price. Individual analyst ratings are listed below the target range.

What is DNTH's EV/EBITDA?

Dianthus Therapeutics, Inc.'s enterprise-value-to-EBITDA multiple is shown on this page. EV/EBITDA is capital-structure neutral (unlike P/E) and is especially useful for comparing companies with different debt levels, a common screen for value investors.